RxDoctor Payments Data

Allen Beecham, DO

Pain Medicine · Canton, GANPI 1578594057

Payments from drug & device makers

$4,101in general payments, 2019–2025

Across 264 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Forte Bio-pharma LLC$503
  • Virtus Pharmaceuticals LLC$361
  • Collegium Pharmaceutical, Inc.$292
  • Redhill Biopharma Inc.$253
  • Pfizer$227
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,101 in reported general payments places this provider in the 60th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$551,203
Medicare patients
348
Services billed
6,846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide70$172,070
Xtampza ErOxycodone Myristate334$133,765
MovantikNaloxegol Oxalate142$58,346
OxycontinOxycodone Hcl70$54,060
Oxycodone Hcl1,912$50,059
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,037$48,936
BelbucaBuprenorphine Hcl48$40,695
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen833$25,021
Buprenorphine36$15,043
Morphine Sulfate ErMorphine Sulfate661$14,317
HorizantGabapentin Enacarbil14$12,887
Lidocaine135$12,679
Hysingla ErHydrocodone Bitartrate13$11,755
Fentanyl110$11,467
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl40$10,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$292$174,460382 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,369$172,07070 claims
Redhill Biopharma Inc.Movantik$253$58,346142 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate, Buprenorphine Hcl$86$29,942252 claims
Arbor Pharmaceuticals, Inc.Horizant$168$12,88714 claims
Virtus Pharmaceuticals LLCLactulose$361$35530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →